JP2009515183A5 - - Google Patents

Download PDF

Info

Publication number
JP2009515183A5
JP2009515183A5 JP2008539508A JP2008539508A JP2009515183A5 JP 2009515183 A5 JP2009515183 A5 JP 2009515183A5 JP 2008539508 A JP2008539508 A JP 2008539508A JP 2008539508 A JP2008539508 A JP 2008539508A JP 2009515183 A5 JP2009515183 A5 JP 2009515183A5
Authority
JP
Japan
Prior art keywords
protein isoform
subject
neurological
affinity reagent
abundance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008539508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009515183A (ja
Filing date
Publication date
Priority claimed from GB0522667A external-priority patent/GB0522667D0/en
Application filed filed Critical
Priority claimed from PCT/GB2006/050375 external-priority patent/WO2007072070A1/en
Publication of JP2009515183A publication Critical patent/JP2009515183A/ja
Publication of JP2009515183A5 publication Critical patent/JP2009515183A5/ja
Pending legal-status Critical Current

Links

JP2008539508A 2005-11-08 2006-11-08 新たなタンパク質アイソフォーム及びその使用 Pending JP2009515183A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0522667A GB0522667D0 (en) 2005-11-08 2005-11-08 New protein isoforms and uses thereof
US73479905P 2005-11-09 2005-11-09
PCT/GB2006/050375 WO2007072070A1 (en) 2005-11-08 2006-11-08 New protein isoforms and uses thereof

Publications (2)

Publication Number Publication Date
JP2009515183A JP2009515183A (ja) 2009-04-09
JP2009515183A5 true JP2009515183A5 (https=) 2009-12-24

Family

ID=37845158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008539508A Pending JP2009515183A (ja) 2005-11-08 2006-11-08 新たなタンパク質アイソフォーム及びその使用

Country Status (4)

Country Link
US (1) US20090311180A1 (https=)
EP (1) EP1999150A1 (https=)
JP (1) JP2009515183A (https=)
WO (1) WO2007072070A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005387A1 (en) * 2008-07-10 2010-01-14 Astrazeneca Ab New method and biomarkers for the diagnosis of multiple sclerosis
DE102008054716A1 (de) * 2008-12-16 2010-06-17 Evonik Degussa Gmbh Inprozesskontrolle in einem Verfahren zur Herstellung von EPO
ES2890501T3 (es) 2009-03-02 2022-01-20 Massachusetts Inst Technology Métodos y productos para la creación de perfiles enzimáticos in vivo
US8778307B2 (en) 2009-06-05 2014-07-15 University Of Maryland, College Park Targeted carriers for drug delivery across the gastrointestinal epithelium
JP5190423B2 (ja) * 2009-08-04 2013-04-24 ホーユー株式会社 2次元電気泳動方法
CA2830235C (en) 2011-03-15 2023-10-24 Massachusetts Institute Of Technology Multiplexed detection with isotope-coded reporters
WO2012151093A1 (en) * 2011-04-30 2012-11-08 Marv Enterprises Llc Treatment for tauopathies
EP3848055A1 (en) 2011-06-03 2021-07-14 Ophidion Inc. Compositions and methods for transport across the blood brain barrier
US9244946B2 (en) 2012-11-26 2016-01-26 International Business Machines Corporation Data mining shape based data
JP6847660B2 (ja) 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
WO2017177115A1 (en) 2016-04-08 2017-10-12 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
US11428689B2 (en) 2016-05-05 2022-08-30 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
CA3059358A1 (en) 2017-04-07 2018-10-11 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
EP3856921B1 (en) 2018-09-25 2026-04-29 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
WO2020150560A1 (en) 2019-01-17 2020-07-23 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
RU2734649C1 (ru) * 2020-02-11 2020-10-21 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Пептид, обладающий активностью белка lynx1 (варианты), фармацевтическая композиция для лечения тревожных расстройств и депрессии или коррекции когнитивных нарушений при нейродегенеративных заболеваниях, содержащая указанный пептид, и способ лечения и коррекции указанных нарушений
WO2020167167A2 (ru) * 2019-02-13 2020-08-20 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Пептид, обладающий активностью белка lynx1, (варианты), фармацевтическая композиция для лечения тревожных расстройств и депрессии или коррекции когнитивных нарушений при нейродегенеративных заболеваниях, содержащая указанный пептид, и способ лечения и коррекции указанных нарушений

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017356A2 (en) * 1998-09-18 2000-03-30 The Rockefeller University Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof
US20020156009A1 (en) * 2000-11-02 2002-10-24 Dennis Ballinger Novel interleukin - 1 Hy2 materials and methods
AU2002330215A1 (en) * 2001-10-03 2003-04-14 Oxford Glycosciences (Uk) Ltd. Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2003083472A1 (en) * 2002-03-29 2003-10-09 Wako Pure Chemical Industries, Ltd. Method of judging risk of peiodontal disease
US20060078890A1 (en) * 2004-10-08 2006-04-13 Ole Isacson Methods for identifying parkinson's disease therapeutics

Similar Documents

Publication Publication Date Title
Reichmann Premotor diagnosis of Parkinson’s disease
Bowser et al. Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations
JP2009515183A5 (https=)
Vercellino et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter
Siderowf et al. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease
Yang et al. Temporal MRI characterization, neurobiochemical and neurobehavioral changes in a mouse repetitive concussive head injury model
Alber et al. Retina pathology as a target for biomarkers for Alzheimer's disease: Current status, ophthalmopathological background, challenges, and future directions
Lin et al. Disease-associated astrocytes and microglia markers are upregulated in mice fed high fat diet
Irimia et al. Cerebral microhemorrhages due to traumatic brain injury and their effects on the aging human brain
CN106461645A (zh) 外伤性脑损伤和神经退行性生物标记物、方法和系统
US20170307640A1 (en) Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury
Barron et al. Assessment of neuroinflammation in a mouse model of obesity and β-amyloidosis using PET
Dede et al. Rapid eye movement sleep without atonia constitutes increased risk for neurodegenerative disorders
Schrempf et al. Reduced intraepidermal nerve fiber density in patients with REM sleep behavior disorder
Velasco et al. Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity
Wilczyńska et al. Serum amyloid biomarkers, tau protein and YKL-40 utility in detection, differential diagnosing, and monitoring of dementia
Slemann et al. Neuronal and oligodendroglial, but not astroglial, tau translates to in vivo tau PET signals in individuals with primary tauopathies
TW202002976A (zh) 治療含有高神經絲輕鏈含量之個體之方法
Schmidt et al. Autonomic dysfunction in patients with progressive supranuclear palsy
JP2025535729A (ja) 神経変性疾患を評価及び治療するためのタンパク質マーカー
Song et al. Blood–brain barrier impairment is functionally correlated with clinical severity in patients of multiple system atrophy
Qaisar et al. Associations of plasma Neurofilament light chain with sarcopenia and physical capacity in patients with Alzheimer’s diseases
Dios et al. Class I and II histone deacetylase expression is not altered in human amyotrophic lateral sclerosis: Neuropathological and positron emission tomography molecular neuroimaging evidence
Pakdaman et al. Efficacy and safety of MLC601 in the treatment of mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled study
Vettermann et al. Noradrenaline transporter availability on [11C] MRB PET predicts weight loss success in highly obese adults